Roy Ananda L, Wilder Elizabeth L, Anderson James M
Office of Strategic Coordination, National Institutes of Health, Bethesda, MD 20892, USA.
Division of Program Coordination, Planning and Strategic Initiatives, Office of the Director, National Institutes of Health, Bethesda, MD 20892, USA.
Sci Adv. 2021 Nov 12;7(46):eabl7148. doi: 10.1126/sciadv.abl7148. Epub 2021 Nov 10.
Large-scale generation of protein capture reagents remains a technical challenge, but their generation is just the beginning. Validation is a critical, iterative process that yields different results for different uses. Independent, community-based validation offers the possibility of transparent data sharing, with use case–specific results made broadly available. This type of resource, which can grow as new validation data are obtained for an expanding group of reagents, provides a community resource that should accompany future reagent-generating efforts. To address a pressing need for antibodies or other reagents that recognize human proteins, the National Institutes of Health Common Fund launched the Protein Capture Reagents Program in 2010 as a pilot to target human transcription factors. Here, we describe lessons learned from this program concerning generation and validation of research reagents, which we believe are generally applicable for future research endeavors working in a similar space.
大规模生成蛋白质捕获试剂仍然是一项技术挑战,但试剂的生成仅仅是个开始。验证是一个关键的迭代过程,不同用途会产生不同结果。基于社区的独立验证提供了透明数据共享的可能性,可广泛提供特定用例的结果。随着为越来越多的试剂获取新的验证数据,这类资源会不断增加,从而形成一种社区资源,应伴随未来的试剂生成工作。为满足对识别人类蛋白质的抗体或其他试剂的迫切需求,美国国立卫生研究院共同基金于2010年启动了蛋白质捕获试剂计划,作为针对人类转录因子的试点项目。在此,我们描述了从该计划中吸取的有关研究试剂生成和验证的经验教训,我们认为这些经验教训通常适用于未来在类似领域开展的研究工作。